Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina

INTRODUCTION: The phase III KEYNOTE-048 trial showed that the programmed death receptor 1 (PD-1) inhibitor pembrolizumab, in the combined positive score (CPS) ≥ 1 population and combined with platinum + 5-fluorouracil in the total population, improves survival over cetuximab + platinum + 5-fluoroura...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Adv Ther
Asıl Yazarlar: Wurcel, Victoria, Chirovsky, Diana, Borse, Rebekah, Altuna, Juan Ignacio, Carabajal, Fernando, Gandhi, Jyotika
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Healthcare 2021
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8107151/
https://ncbi.nlm.nih.gov/pubmed/33855690
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-021-01656-3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller